RESUMO
Laboratory and animal studies have demonstrated that pyrazolopyrimidines have significant activity against Trypanosoma cruzi. This clinical investigation was to ascertain the efficacy of allopurinol in the treatment of chronic Chagas' disease. Of 307 patients studied, 91 were untreated; the remaining 216 were divided into 4 treatment groups. These corresponded to 600 or 900 mg/day of allopurinol for 60 days and benznidazole or nifurtimox at conventional dosage regimens. Patients were evaluated clinically, serologically, and parasitologically. Allopurinol was found to be as efficacious as the conventional therapeutic modalities in eliminating the parasitemia and rendering patients seronegative. Adverse reactions occurred in 11% of patients who received allopurinol and in 30% of those receiving nitrofurans. Reactions with the conventional therapy were more frequent and of a more serious nature. Oral allopurinol is as effective as the nitrofurans, but has none of the side effects.
Assuntos
Alopurinol/uso terapêutico , Doença de Chagas/tratamento farmacológico , Adulto , Alopurinol/efeitos adversos , Doença Crônica , Ensaios Clínicos como Assunto , Feminino , Humanos , Masculino , Nifurtimox/efeitos adversos , Nifurtimox/uso terapêutico , Nitroimidazóis/efeitos adversos , Nitroimidazóis/uso terapêutico , Tripanossomicidas/efeitos adversos , Tripanossomicidas/uso terapêuticoRESUMO
Se estudiaron 58 pacientes en total, siendo 26 mujeres y 32 varones. El promedio de edad fue semejante a los tres grupos (29+/-5,13 anos)La parasitemia fue evaluada mediante xenodiagnosticos seriados (Xd). Cada estudio se realizo con 4 cajas de 10 ninfas del 3er estadio del T. Infestans cada una de acuerdo a la tecnica de Cerisola y Col.> El personal que realizo la lectura en todos los casos ignoraba a que grupo pertenecia el paciente estudiado e igualmente si habia recibido tratamiento o no